Benzogeksony-Zdorovye, solution for infection 2,5% on 1 ml No. 10

General characteristics. Structure:

International and chemical names: 1,6-Bis-(N-trimetil-ammonium) - hexane dibenzol sulphonate; main physical and chemical properties: transparent colourless solution;
structure: 1 ml contains petrolhexonium 25 mg; excipients: water for injections. 

Pharmacological properties:

Pharmacodynamics. The Bischetvertichny ammonium connection having ganglioblokiruyushchy effect of long action.
The mechanism of action is caused by blocking vegetative (sympathetic and parasympathetic) ганглиев that leads to braking of transfer of nervous excitement with preganglionic on postganglionic fibers, dilatation of arterial and venous vessels, reduction of the general peripheric resistance of vessels and very bystry sharp lowering of arterial pressure. The hemodynamic (vazodilatiruyushchy) effect is followed by reduction of pulmonary pressure, deposition of blood in expanded veins of an abdominal cavity and extremities, reduction of venous return to heart. 
Influences carotid balls and chromaffin tissue of adrenal glands that promotes weakening of reflex pressor influences. Interrupting carrying out nervous impulses through vegetative nerve knots, changes functions of the bodies supplied with a vegetative innervation. Causes a lowering of arterial pressure, motility of digestive tract, a tone of a bladder, secretion of excretory glands, breaks accommodation, expands bronchial tubes, increases heart rate.
The hypotensive effect begins in 5–15 min. after introduction, reaches a maximum to the 30th mines and remains during 3–4 h.
Pharmacokinetics. After intravenous administration or a local injection comes to extracellular liquid. Badly gets through fabric barriers (including through hematoencephalic and placental). It is removed in an invariable look through kidneys; during 24 h about 90% of drug are removed. Excretion speed maximum during the first hours after injections.
At a renal failure cumulation can be observed.

Pharmacokinetics. it is studied not completely.

Indications to use:

Spasms of peripheral vessels (endarteritis, the alternating lameness), hypertensive crisis (including complicated by a left ventricular failure), a peptic ulcer of a stomach and duodenum, a bronchospasm; for controlled arterial hypotension.

Route of administration and doses:

Appoint intramusculary, intravenously or subcutaneously. The dosing mode individual in connection with big individual variability of reactions of patients.
Controlled hypotension: enter intravenously 1–1,5 ml (25–37,5 mg) within 2 min.
Hypertensive crisis. For stopping enter intramusculary or subcutaneously 0,5–1 ml (12,5–25 mg). If necessary it is possible to carry out repeated injections (3–4 times a day).
Spasms of peripheral vessels, peptic ulcer of a stomach and duodenum: enter intramusculary or subcutaneously on 0,25–0,5 ml (6,25–12,5 mg) for 1 h to food 2–4 times a day. Treatment is carried out by courses on 2–4–6 weeks with breaks to 1–3 weeks.
The maximum doses for adults at intramuscular and hypodermic introduction: one-time – 3 ml (75 mg), daily – 12 ml (300 mg). 
As the effect of petrolhexonium at repeated introductions gradually decreases, treatment is begun with the smallest doses, and then doses gradually raise.
To children in urgent pediatrics enter intramusculary or intravenously. Intravenously enter slowly (within 6–8 min.), having parted in 10–20 ml of isotonic solution of sodium of chloride or glucose. Single doses for children: up to 2 years – 0,04–0,08 ml/kg (1–2 mg/kg), 2–4 years – 0,02–0,08 ml/kg (0,5–2 mg/kg), are more senior than 5 years – 0,02 ml/kg (0,5 mg/kg). 

Features of use:

Restrictions to a medical use are predisposition to a thrombogenesis, advanced age (the risk of side effects is increased), the pregnancy period (risk of a hypoxia of a fruit), the lactation period (data on use of drug during feeding by a breast are absent).
Treatment should be carried out under careful medical control; at intravenous administration constantly control arterial pressure.
In order to avoid development of a collapse the patient before introduction and during 2–2,5 h after it has to be in horizontal position. 
At development of an atony of intestines or bladder introduction of a prozerin, Galantaminum or other cholinomimetic or antikholinesterazny drugs is reasonable.
Before therapy it is necessary to carry out the individual sensitivity test for what enter ½ average doses and control a condition of the patient.
To petrolhexonium accustoming rather quickly develops that demands increase in a dose.
During treatment it is necessary to abstain from control of vehicles and performance of potentially dangerous types of activity because of a possibility of development of side effects from the central and cardiovascular systems.

Side effects:

From the central nervous system: weakness, dizziness, expansion of pupils, short-term decrease in memory, dysarthtia, respiratory depression. From cardiovascular system: increase of pulse, orthostatic hypotension (up to development of a collapse), tachycardia, pains in heart, an injection of vessels of scleras. From digestive tract: dryness in a mouth, a dysphagy, a lock; at prolonged use – an atony of intestines and paresis of a gall bladder. From an urinary system: at prolonged use – a bladder atony, the disturbance of an urination with stagnation of urine promoting development of cystitis.

Interaction with other medicines:

Drug increases efficiency of adrenomimetik (noradrenaline, a phenylephine hydrochloride, Isadrinum, etc.) and cholinomimetics (Pilocarpinum, Carbacholinum, etc.). Mutually strengthens action of venous vazodilatator, antihistaminic, narcotic, hypnagogues, neuroleptics, tricyclic antidepressants, local anesthetics, anti-hypertensive drugs. At combined use with MAO inhibitors development of a collapse is possible. Increases sensitivity of patients with a diabetes mellitus to insulin. Efficiency of drug is reduced by emetic, antikholinesterazny medicines and N-holinostimulyatory.

Contraindications:

Hypersensitivity to drug, arterial hypotension, a hypovolemia and shock, a pheochromocytoma, a myocardial infarction in an acute stage, an ischemic stroke (up to 2 months), fibrinferments (including brain arteries), closed-angle glaucoma, a liver and/or renal failure, degenerative changes of the central nervous system.

Overdose:

At overdose the orthostatic collapse can develop. Treatment: the patient is given situation with the hung head and the raised legs, introduction of a phenylephine hydrochloride, Phethanolum or ephedrine in small doses, Cordiaminum, caffeine.

Storage conditions:

To store in the place protected from light at a temperature from 8 °C to 25 °C. To store in the place, unavailable to children. 
Period of validity – 4 years.

Issue conditions:

According to the recipe

Packaging:

On 10 ampoules on 1 ml in a pack.